GlassScriptPhysician profile
Iqbal S Jangda
NPI 1467537175
$7,661.55
in general payments reported to CMS, 2019-2025
23 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $286 · 2021: $796 · 2022: $1,138 · 2023: $1,131 · 2024: $1,863 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,316.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,002.63 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Glaxosmithkline, LLC. | $997.96 | 2021-2025 | Nucala, Arexvy |
| Neurocrine Biosciences, INC. | $805.59 | 2019-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $758.90 | 2019-2025 | Breztri |
| Abbvie INC. | $693.45 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $383.14 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.22 | 2019-2020 | |
| Abbott Laboratories | $303.90 | 2021-2023 | Pressurewire |
| Philips North America LLC | $285.78 | 2019-2022 | |
| Lundbeck LLC | $273.24 | 2019-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $249.70 | 2021-2024 | |
| Insmed, INC. | $249.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $242.83 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $225.45 | 2019-2024 | Invega Trinza, Invega Sustenna |
| Phathom Pharmaceuticals, INC. | $149.18 | 2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $125.00 | 2024 | Inpefa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.89 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $123.62 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $122.13 | 2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $121.82 | 2025 | Ozempic |
| Alkermes, INC. | $57.72 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $22.90 | 2022 | |
| Almatica Pharma LLC | $22.85 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqbal Jangda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.